股腘动脉DCB术后补救性支架植入的影响因素及应对策略
Influencing Factors and Coping Strategies of Bailout Stent Implantation after Drug-Coated Balloon Angioplasty for Femoropopliteal Artery Disease
摘要: 股腘动脉病变是导致下肢缺血的主要原因，药物涂层球囊(DCB)虽已在临床上取得了相对确切的疗效，但术后仍有一定比例的患者需接受补救性支架植入。本文依据国内外相关研究，从病变程度及钙化程度、基于TASC II分级的病变复杂程度、弹性回缩及限流性夹层、血管炎症反应与内膜增生，以及合并全身性疾病等多个方面，分析影响补救性支架植入的关键因素。在此基础上，提出包括器械选择、操作技术与临场判断、围术期管理以及影像学辅助在内的综合应对策略，旨在设计出更加个体化、前瞻性的精准治疗方案，减少植入或更优地植入补救性支架，从而改善患者远期预后。
Abstract: Femoropopliteal artery disease is a major cause of lower limb ischemia. Although drug-coated balloons (DCB) have achieved relatively definite clinical efficacy, a certain proportion of patients still require bailout stent implantation after the procedure. Based on relevant domestic and international studies, this paper analyzes the key factors influencing bailout stent implantation from multiple aspects, including lesion length and degree of calcification, lesion complexity based on the TASC II classification, elastic recoil and flow-limiting dissection, vascular inflammatory response and intimal hyperplasia, and concomitant systemic diseases. On this basis, comprehensive coping strategies are proposed, covering device selection, operative technique and intraoperative judgment, perioperative management, and imaging assistance, aiming to design more individualized and forward-looking precise treatment plans that reduce stent implantation or achieve more optimal bailout stent placement, thereby improving the long-term prognosis of patients.
文章引用：侯泽文, 霍艳兵. 股腘动脉DCB术后补救性支架植入的影响因素及应对策略[J]. 临床医学进展, 2026, 16(8): 1936-1943. https://doi.org/10.12677/acm.2026.1682980

参考文献

[1] 王承芳, 余朝文, 任天才, 等. 股腘动脉支架内再狭窄患者药物涂层球囊血管成形术后1年再狭窄的影响因素分析[J]. 中华解剖与临床杂志, 2023, 28(6): 388-394.
[2] Ma, H., Zhang, X., Li, J., Li, Q., Li, W., Jiao, Y., et al. (2022) Mid-Term Efficacy and Safety of Drug-Coated Balloon versus Nitinol Bare Metal Stent for Primary Lesions in Femoropopliteal Artery Disease. Annals of Vascular Surgery, 81, 316-323.
https://doi.org/10.1016/j.avsg.2021.09.022
[3] Nakama, T., Takahara, M., Iwata, Y., Suzuki, K., Tobita, K., Hayakawa, N., et al. (2025) 3-Year Outcomes of Drug-Eluting Stent vs Drug-Coated Balloon for Femoropopliteal Artery Lesions: Propensity Score-Matched Real-World Study. JACC: Cardiovascular Interventions, 18, 2155-2166.
https://doi.org/10.1016/j.jcin.2025.07.034
[4] Kokkinidis, D.G., Jeon-Slaughter, H., Khalili, H., Brilakis, E.S., Shammas, N.W., Banerjee, S., et al. (2018) Adjunctive Stent Use during Endovascular Intervention to the Femoropopliteal Artery with Drug Coated Balloons: Insights from the XLPAD Registry. Vascular Medicine, 23, 358-364.
https://doi.org/10.1177/1358863x18775593
[5] Mohapatra, A., Saadeddin, Z., Bertges, D.J., Madigan, M.C., Al-Khoury, G.E., Makaroun, M.S., et al. (2020) Nationwide Trends in Drug-Coated Balloon and Drug-Eluting Stent Utilization in the Femoropopliteal Arteries. Journal of Vascular Surgery, 71, 560-566.
https://doi.org/10.1016/j.jvs.2019.05.034
[6] Yoshioka, N., Tokuda, T., Tanaka, A., Kojima, S., Yamaguchi, K., Yanagiuchi, T., et al. (2026) Comparing the Clinical Performance of Paclitaxel‐Coated Balloons and Paclitaxel‐Eluting Stent for Treating Long Femoropopliteal Artery Disease: Results of the CAPELLA Study. Catheterization and Cardiovascular Interventions, 107, 567-576.
https://doi.org/10.1002/ccd.70387
[7] Norgren, L., Hiatt, W.R., Dormandy, J.A., Nehler, M.R., Harris, K.A. and Fowkes, F.G.R. (2007) Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II). Journal of Vascular Surgery, 45, S5-S67.
https://doi.org/10.1016/j.jvs.2006.12.037
[8] Haraguchi, T., Tsujimoto, M., Kasai, Y., Kashima, Y., Sato, K. and Fujita, T. (2026) Full-Coverage Drug-Eluting Stent vs Drug-Coated Balloon in De Novo Femoropopliteal Lesions: Three-Year TASC II-Stratified Outcomes. Journal of Endovascular Therapy.
https://doi.org/10.1177/15266028261420088
[9] Bausback, Y., Wittig, T., Schmidt, A., Zeller, T., Bosiers, M., Peeters, P., et al. (2019) Drug-Eluting Stent versus Drug-Coated Balloon Revascularization in Patients with Femoropopliteal Arterial Disease. Journal of the American College of Cardiology, 73, 667-679.
https://doi.org/10.1016/j.jacc.2018.11.039
[10] 李鑫奕, 邹雨池, 童强, 等. 股腘动脉疾病行经皮腔内血管成形术后严重弹性回缩的风险预测: 基于血管内超声的分析[J]. 中国普外基础与临床杂志, 2025, 32(4): 463-467.
[11] Fujihara, M., Takahara, M., Sasaki, S., Nanto, K., Utsunomiya, M., Iida, O., et al. (2017) Angiographic Dissection Patterns and Patency Outcomes after Balloon Angioplasty for Superficial Femoral Artery Disease. Journal of Endovascular Therapy, 24, 367-375.
https://doi.org/10.1177/1526602817698634
[12] Wang, Y., Moura, A.K., Zuo, R., Guan, Y., Lee, E.A., Hu, J.Z., et al. (2025) Contribution of NLRP3-GSDMD Axis to PDGF-BB-Induced Vascular Smooth Muscle Cell Phenotypic Transition. American Journal of Physiology-Cell Physiology, 329, C682-C698.
https://doi.org/10.1152/ajpcell.00226.2025
[13] Kan, Q., Peng, Z., Wang, K., Deng, T., Zhou, Z., Wu, R., et al. (2024) Vascular Restenosis Following Paclitaxel-Coated Balloon Therapy Is Attributable to NLRP3 Activation and LIN9 Upregulation. Journal of Translational Medicine, 22, Article No. 871.
https://doi.org/10.1186/s12967-024-05657-y
[14] Yang, L., Quan, J., Dong, J., Ding, N., Han, Y., Cong, L., et al. (2024) Comparison of Mid-Outcome among Bare Metal Stent, Atherectomy with or without Drug-Coated Balloon Angioplasty for Femoropopliteal Arterial Occlusion. Scientific Reports, 14, Article No. 63.
https://doi.org/10.1038/s41598-023-50511-8
[15] Roh, J.W., Ko, Y., Ahn, C., Hong, S., Shin, D., Kim, J., et al. (2019) Risk Factors for Restenosis after Drug-Coated Balloon Angioplasty for Complex Femoropopliteal Arterial Occlusive Disease. Annals of Vascular Surgery, 55, 45-54.
https://doi.org/10.1016/j.avsg.2018.06.015
[16] Zhao, H., Ma, B., Chen, J., Zheng, L., Sun, C., Sun, M., et al. (2021) Drug-Coated Balloon versus Bare Nitinol Stent in Femoropopliteal Artery: 12 Months Outcome from a Single Center in China. Annals of Vascular Surgery, 74, 367-381.
https://doi.org/10.1016/j.avsg.2021.01.079
[17] Hanna, J., Smolderen, K.G., Castro‐Dominguez, Y., Romain, G., Lee, M., Turner, J., et al. (2023) Drug‐Coated Balloon and Drug‐Eluting Stent Safety in Patients with Femoropopliteal and Severe Chronic Kidney Disease. Journal of the American Heart Association, 12, e028622.
https://doi.org/10.1161/jaha.122.028622
[18] Boc, A., Eržen, B., Perme, R.L. and Boc, V. (2022) Bailout Stenting in Femoropopliteal Arterial Segment. Vasa, 51, 13-18.
https://doi.org/10.1024/0301-1526/a000986
[19] Ogata, K., Nishihira, K., Tokuda, T., Yoshioka, N., Tanaka, A., Kojima, S., et al. (2025) Drug‐Eluting Stent and Drug‐coated Balloon Compared to Full‐Covered Drug‐Eluting Stent for Femoropopliteal Lesions: CENTAUR Study. Catheterization and Cardiovascular Interventions, 106, 1600-1609.
https://doi.org/10.1002/ccd.31727
[20] Zhou, Y., Zhang, Z., Lin, S., Xiao, J., Ai, W., Wang, J., et al. (2020) Comparative Efficacy and Safety of Endovascular Treatment Modalities for Femoropopliteal Artery Lesions: A Network Meta-Analysis of Randomized Controlled Trials. CardioVascular and Interventional Radiology, 43, 204-214.
https://doi.org/10.1007/s00270-019-02332-4
[21] Wei, L., Guo, J., Guo, L., Qi, L., Cui, S., Tong, Z., et al. (2022) Directional Atherectomy and Drug-Coated Balloon Angioplasty vs. Bare Nitinol Stent Angioplasty for Femoropopliteal Artery Lesions. Vasa, 51, 275-281.
https://doi.org/10.1024/0301-1526/a001010
[22] Lawton, J.S., Tamis-Holland, J.E., Bangalore, S., Bates, E.R., Beckie, T.M., Bischoff, J.M., et al. (2021) ACC/AHA/SCAI Guideline for Coronary Artery Revascularization: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Journal of the American College of Cardiology, 79, e21-e129.
https://doi.org/10.1016/j.jacc.2021.09.006
[23] Basavarajaiah, S., Sharma, V., Agip-Fustamante, D., Camacho Freire, S.J., EL-Mokdad, R., Bhatia, G., et al. (2023) Which Predilatation Balloons Provide the Best Lesion Preparation Prior to Use of Drug Coated Balloons in De-Novo Lesions? Results from the PREPARE Study. Minerva Cardiology and Angiology, 71, 182-188.
https://doi.org/10.23736/s2724-5683.22.05989-0
[24] Mok, K.H., Wickramarachchi, U., Watson, T., Ho, H.H., Eccleshall, S. and Ong, P.J.L. (2017) Avoid Stent Insertion in Drug-Coated Balloon Angioplasty. Herz, 42, 698-698.
https://doi.org/10.1007/s00059-017-4543-8
[25] Corballis, N.H., Merinopoulos, I., Natarajan, R., Gunawardena, T., Wickramarachchi, U., Vassiliou, V.S., et al. (2025) Safety Aspects of De Novo DCB-Only PCI—A Practical Checklist and a Simplified Revised Dissection Classification. Frontiers in Cardiovascular Medicine, 12, Article ID: 1655201.
https://doi.org/10.3389/fcvm.2025.1655201
[26] Moubarak, G., Gupta, A., Jeong, M., et al. (2026) Dual Versus Non-Dual Anti-Platelet Therapy and Major Adverse Limb Outcomes Following Stent or Nonstent Strategies for Symptomatic Peripheral Artery Disease in the XLPAD Registry. JACC: Cardiovascular Interventions, 19, S36.
[27] Conte, M.S., Aulivola, B., Barshes, N.R., Bertges, D.J., Corriere, M.A., Murad, M.H., et al. (2025) Society for Vascular Surgery Clinical Practice Guideline on the Management of Intermittent Claudication: Focused Update. European Journal of Vascular and Endovascular Surgery, 70, e25.
https://doi.org/10.1016/j.ejvs.2025.07.005
[28] Lee, S.J., Kim, T.H., Lee, J.H., Ahn, C., Lee, S., Lee, Y., et al. (2025) Intravascular Ultrasound-Guided vs Angiography-Guided Drug-Coated Balloon Angioplasty in Patients with Complex Femoropopliteal Artery Disease. JACC: Cardiovascular Interventions, 18, 558-569.
https://doi.org/10.1016/j.jcin.2024.10.052
[29] Roh, J.W., Fujihara, M., Yazu, Y., Tsukizawa, T. and Yokoi, Y. (2025) Long‐Term Clinical Association of Superficial and Nodular Calcification on Intravascular Ultrasound‐guided Successful Drug‐Coated Balloon Endovascular Therapy for De Novo Femoropopliteal Artery Disease. Catheterization and Cardiovascular Interventions, 106, 2744-2752.
https://doi.org/10.1002/ccd.70117

为你推荐